カワムラ　ヒデマサ   KAWAMURA Hidemasa   河村　英将    所属   埼玉医科大学  医学部 総合医療センター　放射線科(画像診断・核医学科、放射線腫瘍科)    職種   教授
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読あり
表題	Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT Consortium
掲載誌名	正式名：BRACHYTHERAPY ISSNコード：1538-4721/1873-1449
出版社	ELSEVIER SCIENCE INC
巻・号・頁	16(3),503-510頁
著者・共著者	Hiromichi Ishiyama,Nobuhiko Kamitani,Hidemasa Kawamura,Shingo Kato,Manabu Aoki,Shinji Kariya,Taisei Matsumura,Motoki Kaidu,Ken Yoshida,Yaichiro Hashimoto,Yasutaka Noda,Keith H. C. Lim,Takatsugu Kawase,Takeo Takahashi,Koji Inaba,Motoyasu Kumano,Nobuhiko Yoshikawa,Yasuo Yoshioka,Katsumasa Nakamura,Junichi Hiratsuka,Jun Itami,Kazushige Hayakawa
発行年月	2017/05
概要	PURPOSE: To report outcomes and risk factors of high-dose-rate (HDR) brachytherapy combined with external beam radiotherapy with or without androgen deprivation therapy (ADT) in prostate cancer patients. MATERIALS AND METHODS: This multi-institutional retrospective analysis comprised 3424 patients with localized prostate cancer at 16 Asian hospitals. One-thirds (27.7%) of patients received only neoadjuvant ADT, whereas almost half (49.5%) of patients received both neoadjuvant and adjuvant ADT. Mean duration of neoadjuvant and adjuvant ADT were 8.6 months and 27.9 months, respectively. Biochemical failure was defined by Phoenix ASTRO consensus. Biochemical control rate, clinical disease-free survival (cDFS), cause-specific survival, and overall survival (OS) were calculated. RESULTS: Median followup was 66 months. Ten-year biochemical control, cDFS, cause-specific survival, and OS rate were 81.4%, 81.0%, 97.2%, and 85.6%, respectively. Receiving both neoadjuvant and adjuvant ADT was detected as a favorable factor for biochemical control, cDFS, and OS, but pelvic irradiation was detected as an adverse factor for cause-specific survival, and OS. Ten-year cumulative rates of late Grade >= 2 genitourinary and gastrointestinal toxicities were 26.8% and 4.1%, respectively; receiving both neoadjuvant and adjuvant ADT was detected as a favorable factor for preventing both toxicities. CONCLUSIONS: HDR combined with external beam radiotherapy was an effective and safe treatment for localized prostate cancer. Combination of long-term ADT was suggested to be necessary, even for HDR brachytherapy, and was useful in suppressing late toxicities. Meanwhile, pelvic irradiation was suggested to have an adverse effect on OS of our study population. (C) 2017 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
DOI	10.1016/j.brachy.2017.01.006
PMID	28222973